OBJECTIVE: This study was conducted to elucidate whether antagonistic targeting of the histamine H 3 receptor increases hypothalamic histamine levels, in parallel with decreases in food intake and body weight.
Introduction
There is accumulating evidence that histaminergic neural circuits arising in the tuberomammillary nucleus and projecting into the satiety centres of the hypothalamus participate in regulation of energy homeostasis. [1] [2] [3] [4] The very central function of neural histamine in regulation of food intake 1, [5] [6] [7] is further underlined by the fact that leptin, 8, 9 amylin 10,11 and bombesin 12 have been suggested to exert their anorectic effects through histaminergic circuits. In accordance herewith, histamineric neurons project into hypothalamic centres known to participate in food intake regulation: the paraventricular nucleus (PVN) and ventromedial hypothalamus (VMH), where the anorectic effect is thought to be mediated by postsynaptic histamine H 1 receptors. 5, 13 The density of this receptor 14 together with the H 3 -receptor-mediated control of the intrasynaptic concentration of histamine both seem to be crucial for the strength of the anorectic signal. The intrasynaptic concentration of histamine is primarily controlled by feedback signals from presynaptic histamine H 3 receptors 15 that inhibit both the conversion of L-histidine to histamine 7 and the release of histamine into the synaptic cleft. 15, 16 Thus, by reducing this inhibition, using a selective histamine H 3 receptor antagonist, the synaptic concentration of histamine should increase together with the signalling from the histamine H 1 receptor, and food intake should consequently be inhibited.
The present work was conducted to investigate this hypothesis, and we report here the effects of the specific histamine H 3 receptor antagonist, NNC 0038-000-1049 (NNC 38-1049), on hypothalamic histamine levels, energy homeostasis and body weight.
Methods

Test compound
By testing the series of monoacyldiamines, 1-alkyl-4-(4-aryl-4-oxobutanoyl) piperazines were identified as novel, imidazole-free histamine H 3 receptor antagonists. 17 Among these, 1-cyclopentyl-4-(4-(4-chlorophenyl)-4-oxobutanoyl) piperazine, denoted NNC 0038-0000-1049, abbreviated NNC 38-1049, (Figure 1 ) was selected for further in vivo profiling. This compound was prepared from 1-cyclopentylpiperazine (Emka-Chemie, D-85375 Neufahrn, Germany) and 4-(4-chlorophenyl)-4-oxobutanoic acid (Sigma-Aldrich, St Louis, MO, USA) using standard amide-bond-formation methodology (1-hydroxybenzotriazole, N-ethyl-N 0 -(3-dimethylaminopropyl) carbodiimide hydrochloride, dimethylformamide, 201C, 4 h), and was subsequently converted to a hydrochloride salt by co-evaporation with hydrochloric acid and recrystallization of the resulting salt from ethanol.
In vitro characteristics
The in vitro characteristics of NNC 38-1049 were investigated using a Flash Plate s cAMP assay (NENt Life Science Products) as described previously. 18 Briefly, intact HEK293 cells, stably expressing the human or rat histamine H 3 receptor, were treated with isoprenaline in order to stimulate cAMP generation. The ability of the H 3 receptor agonist R-a-methylhistamine (RAMHA) to inhibit the isoprenalineinduced accumulation of cAMP was determined, and EC 50 values were calculated by nonlinear regression analysis of the dose-response curve using GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA, USA H-histamine as radiolabelled ligand.
Animals, diets and ethics
In the present study, 8-9-week-old male Sprague-Dawley rats purchased from Møllegård Breeding and Research Centre (Lille Skensved, Denmark) and given normal rat chow were employed as the standard model for studies of various acute effects of NNC 38-1049. Longer-term effects (2 weeks) on food intake and body weight were studied in 17-month-old female Wistar rats (Møllegård Breeding and Research Centre, Lille Skensved, Denmark) in which dietary obesity had been induced as previously described (DIO rats). 19 Effects of NNC 38-1049 on hypothalamic histamine release were studied in male albino Wistar rats from Harlan (Zeist, the Netherlands). After purchase, rats were acclimatized to the experimental environment for 2-4 weeks before the start of experiments. On arrival, rats were placed in conventional rat cages harbouring 2-3 animals. About 7-10 days before recording of food intake was initiated, animals were moved to single cages. Unless otherwise stated, rats were subjected to a 12/12 h light/dark regime, and room temperature was held between 20 and 231C. Food was either freely available at all times or during a certain time period of 5-7 h (schedule feeding, see below). Water remained freely available, and rats were weighed weekly. Diets were purchased from a local feed manufacturer (Brogaarden, Gentofte, Denmark). All experiments were performed in accordance with the Declaration of Helsinki and approved by the local ethical committies, viz. Neural histamine and food intake K Malmlöf et al the Faculty of Mathematics and Natural Science (University of Groningen, the Netherlands).
Plasma and hypothalamic levels of NNC 38-1049 following single dose Rats were given single oral doses of NNC 38-1049 in doses ranging from 0 to 60 mg/kg 1 h before being decapitated without prior anaesthesia. Each dose group consisted of four randomly assigned rats. Blood was collected in EDTA-coated tubes, and the hypothalami were quickly dissected out and frozen in liquid nitrogen. After decantation, plasma was stored at À801C until analysed. The hypothalami were homogenized in methanol for 30 s at 13 500 rpm using an Ultra Turrax T25 (Janke & Kunkel, Staufen, Germany). Aliquots of 1000 ml of the homogenates diluted with 1500 ml methanol were homogenized for 20 s, followed by centrifugation for 10 min at 724 g and decantation.
Further treatment of the supernatants is described in the 'Analyses' section.
Microdialysis of hypothalamic histamine following single dose Animals were first anaesthetized using isoflurane (2.5%, 400 ml/min N 2 O, 600 ml/min oxygen (O 2 )), after which holes were drilled in the skull overlying the PVN. Home-made I-shaped probes (Hospal AN 69) with a dialysable surface of 2 mm were slowly inserted in the PVN. Co-ordinates of implantation were: posterior to bregma À1.9 mm, lateral to midline þ 1.5 mm and ventral to dura À9.0 mm, at an angle of 101. Probes were secured with dental cement and surgical screws.
Experiments were performed 24-48 h after surgery. Probes were perfused with an artificial cerebrospinal fluid (aCSF), containing 147 mM NaCl, 3.0 mM KCl, 1.2 mM CaCl 2 and 1.2 mM MgCl 2 at a flow rate of 1.5 ml/min. Concomitantly, 20 min microdialysis samples were collected online in highperformance liquid chromatography (HPLC) loops and injected automatically into the column. After basal levels of histamine were established, NNC 38-1049 or vehicle (saline) was injected intraperitoneally (i.p.) in 1 ml/kg volumes.
Tests of unspecific effects
Behaviour satiety sequence (BSS). Studies of the BSS were performed essentially as described by Halford and Blundell. 20 Following a 24 h fast, rats received oral or i.p. administration of NNC 38-1049 in doses ranging from 0 to 20 mg/kg (n ¼ 8). They were thereafter allowed access to a food bowl (10 cm +; 3 cm high) filled with granulated standard lab chow mixed with tap water (50/50; 1 kg granulate/l tap water).
The behaviour of rats was recorded manually once every 15 s for 40 min, and their behaviour was classified as: eating active (locomotion, rearing or sniffing) grooming (licking, scratching, stroking or biting of any part of the body) resting These recordings were clustered on an individual basis in eight bins of 5 min containing a total of 20 observations. Within these 5-min bins, the frequency of each type of behaviour was expressed as a proportion. Thus, for example, if an individual rat was observed eating five times out of 20, the corresponding proportion became 0.25. The same was done for all four classes of behaviour. Data of this type for animals belonging to the same group and 5-min bin were subsequently used for calculation of means and are represented as such.
Pica behaviour (kaolin consumption). Standard food and kaolin pellets (99% kaolin and 1% gum arabic) were fed to rats in two identical containers for 7 days. The rats were housed in cages with an elevated grid floor and standard bedding underneath. Thereafter, standard bedding was substituted with filter paper, and baseline kaolin consumption was measured for 24 h. On day 9, about 30-45 min before the start of the dark period, the animals received vehicle or oral doses of NNC 38-1049 (10, 15 and 20 mg/kg) and were placed in clean cages with fresh filter paper. The anticancer drug Cisplatin (5 mg/kg, Sigma-Aldrich, St Louis, MO, USA) was used as positive control. All groups of rats received fresh water, food and kaolin pellets. Consumption of food and kaolin pellets was recorded over a 16-h period, including a 12-h night period.
Conditioned taste aversion (CTA). A 7-day subchronic CTA paradigm was adopted in order to examine whether NNC 38-1049 induced CTA following repeated administration. Rats were allowed to adapt to single cages for 1 week before they were given water in two identical bottles instead of one, and were switched over to a reversed day-light cycle with lights off between 0900 and 2100 h. When daily water intake had become stable, animals were divided into three groups (n ¼ 8), which on average consumed the same amount of water. One of these groups received daily i.p. injections of vehicle, a second group received the reference compound lithium chloride (LiCl, 40 mg/kg) and a third group was given NNC 38-1049 (20 mg/kg). Immediately following the first dose, and throughout the 1-week injection period, the water in both bottles was replaced with fresh-made saccharin solution (1 g/l). This supply was withdrawn exactly 24 h after the last dosing, and both bottles were again filled with water alone for another 24 h period. Following this, rats were given access to one bottle filled with saccharin, and another filled with water. This two-bottle preference test was maintained for 24 h. During this time, saccharin intake, water intake, total fluid intake and the ratio saccharin/total fluid were registered. The volume of saccharine solution consumed in relation to total fluid intake was used as a measure of CTA, Neural histamine and food intake K Malmlöf et al evoked by treatments, and is expressed as % saccharin intake.
Effects on the hypothalamic-pituitary-adrenal (HPA) axis. Rats were injected i.p. with vehicle (n ¼ 4) or NNC 38-1049 (n ¼ 4) immediately prior to the beginning of a 5-h schedule-feeding period. After 90 min, they were decapitated, and blood was collected in EDTA-coated tubes and centrifuged. The plasma was stored at 801C until analysed for corticosterone.
Food intake, energy expenditure and substrate oxidation following single dose Food-intake experiments were performed with animals that had been adapted to a 7-h feeding schedule within the light period. On the test day, groups (n ¼ 15) of animals received single oral administrations of NNC 38-1049 in doses ranging from 0 to 60 mg/kg just before presentation of food, after which food consumption was recorded for 3 h. Data are presented as accumulated food intake. O 2 consumption was used as a measure of energy expenditure and the respiratory exchange ratio (RER), that is, the ratio of carbon dioxide (CO 2 ) production to O 2 consumption, was employed as a measure of the type of substrate being oxidized. This exchange of gases was studied using an Oxymax equal flow system (Columbus Instruments, Columbus, OH, USA). The system was calibrated daily before the start of measurements.
After a 2.5-h period of adaptation to the Oxymax chambers, rats received a single oral administration of NNC 38-1049 in doses ranging from 0 to 60 mg/kg, and measurements were continued for an additional 2.5-h period. O 2 and CO 2 concentrations in the reference air and in the chambers were measured every 16.9 min. O 2 consumption was calculated per metabolic weight (kg live weight 0.75 ).
Intakes of food and water, body weight and plasma variables following repeated dosing This 15-day experiment was performed in DIO rats that had been adapted to a 7-h feeding schedule within the light period. One administration was performed just before presentation of food and another was carried out 3.5 h later. Rats were randomly assigned to groups (n ¼ 14-15) receiving one of the following treatments: vehicle alone, vehicle in combination with 25% food restriction, or NNC 38-1049 in doses of either 2 Â 10 or 2 Â 20 mg/kg. NNC 38-1049 was given orally during the first 5 days, but this route of administration was subsequently changed to i.p. administration in order to avoid the day-to-day variation in the effect on food intake that was observed with oral administration, which might have been related to some discomfort to the animals resulting from the frequent oesophageal intubations. Animals were kept in single cages during foodintake recordings, with free access to water and with access to food for 7 h per day. Body weights were recorded at the start of treatment, after 9 days, and at the termination of treatment. The amount of food consumed during these time intervals was estimated by subtracting the residual food recovered from each cage from the total amount presented. The accumulated daily water intake was measured in a similar fashion, and, in addition, detailed 7-h recordings of water intake were performed in direct association with administrations on days 1, 8 and 11. These data were pooled for each single rat and are presented as the 7-h mean water intake. On the last day of treatment, the unanaesthetized animals were killed by decapitation. After bleeding, serum and plasma were prepared and frozen at À801C. Body composition was determined by dual X-ray scanning (Dexa) on exsanguinated carcasses after decapitation.
Analyses
Quantitative analysis of NNC 38-1049 in plasma and brain. The concentration of NNC 38-1049 in supernatants from hypothalami extracts and plasma was measured by HPLC and tandem mass spectrometry (LC-MS-MS). Shortly before analysis, 100 ml of plasma was mixed with 100 ml 0.1% formic acid in methanol, and 100 ml supernatant of brain extract was added to 100 ml 0.1% formic acid in water. The mixtures were centrifuged for 20 min at 16 452 g and the supernatants were analysed by use of Cohesive Technologies TurboFlow chromatography (Bucks, UK). An Oasis HLB column (1.0 Â 50 mm) was employed with a 5-95% 0.1% formic acid-methanol gradient system and a total runtime of 1.67 min. A Sciex API 3000 mass spectrometer (Toronto, Canada) was run in positive ionization multiple reaction monitoring (MRM) mode for specific detection of the compound. Calibration curves were prepared with NNC 38-1049 dissolved either in plasma or in the supernatant of brain extract in the concentration range 10-3000 ng/ml.
Analysis of histamine in dialysates
Histamine from microdialysis samples was separated on a reversed-phase HPLC column (100 Â 2.0 mm C18 Hypersil 3 mm column (Bester, Amstelveen, the Netherlands)). The mobile phase consisted of 0.16 M KH 2 PO 4 , 0.4 mM sodium octane sulphate, 0.1 mM EDTA and 1% of methanol (pH 4.5), and was delivered by a Pharmacia LKB 2150 pump (Pharmacia, Uppsala Sweden) at a flowrate of 0.4 ml/min.
Upon separation, histamine was derivatized postcolumn by mixing of the mobile phase with a 0.002% m/v solution of OPA in 0.15 M NaOH solution through a T-piece. The flowrate of the derivatization pump (Shimadzu LC-10AD) was 0.5 ml/min. The mobile phase and the derivatization agent were connected by a T-piece, followed by a metal mixing coil (ID 0.55 mm, OD 1.1 mm, length 1 m; dimension 3 Â 10 cm, insulated with cotton wool). The derivatization reaction was performed at ambient temperature.
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Metabolites and hormones
Plasma or serum concentrations of metabolites were analysed using a Synchron CX5 auto-analyser system (Beckman Instruments, Fullerton, CA, USA), employing standard methods. Corticosterone was analysed using a solid-phase radioimmunoassay (Diagnostic Products Corporation, CA, USA) with maximum intra-and interassay coefficients of variation of 12 and 15%, respectively.
Statistics
Statistical calculations were performed using Graph Pad Prism version 3.0. (GraphPad Software, San Diego CA, USA) or SAS version 8.2 (SAS Institute, Cary, NC, USA). Potential differences between treatment groups, exhibiting normally distributed data, were tested by one-way analyses of variance followed by Dunnett's post hoc test for multiple comparisons. In other cases, data were analysed by nonparametric one-way analysis of variance (Kruskal-Wallis test) using Dunn's post hoc test for multiple comparisons. Comparisons having a Pvalue of less than 0.05 were considered to be statistically significant. Data are presented as the means7s.e.m. unless otherwise stated. In the figures, significant statistical differences between means are marked as follows: *Po0.05, **Po0.01, ***Po0.001.
Results
In vitro characteristics NNC 38-1049 was found to be a potent competitive antagonist at the human histamine H 3 receptor. In the cAMP assay, K b values of 2.370.63 nM (n ¼ 3) were determined. A representative Schild plot is shown in Figure 2 , and in that particular experiment the K b value was 2.7 nM. These K b values agree well with the competitive antagonist potency values on the human H 3 receptor determined in a membrane-based, func- Plasma and hypothalamic levels of NNC 38-1049 following a single dose Measurable amounts of NNC 38-1049 were found in plasma following oral doses of 3-60 mg/kg and in the brain after 15-60 mg/kg (Figure 3 ).
Hypothalamic histamine levels following single dose NNC 38-1049 at an i.p. dose of 20 mg/kg, was found to produce a sharp rise in the concentration of histamine in dialysates recovered from the PVN. This rise was found to be statistically significant (Po0.05) in the period from 20 to 100 min following administration. A dose of 5 mg/kg also seemed to produce a slight, but yet statistically insignificant, increase ( Figure 4 ).
Tests of unspecific effects
Behaviour satiety sequence (BSS). I.p. administration of NNC 38-1049 did not cause a disruption of the behavioural pattern of rats after presentation of food, as determined by observation of BSS ( Figure 5 ). All the components of behaviour were represented in a fairly similar sequence regardless of whether rats were given vehicle or NNC 38-1049. A tendency to spend a little less time eating in the beginning of the 40-min observation period could, however, be noticed in rats given NNC 38-1049. When the areas under the curves were integrated for the whole 40-min period and statistically compared, no differences between groups were found for any of the behaviour classes. Following oral dosing, a slight activity increase was seen at doses of 10 and 15 mg/kg, whereas activity had returned to normal at 20 mg/kg (data not shown).
Pica behaviour (kaolin consumption). There were no significant effects of NNC 38-1049 on pica behaviour (Figure 6 ), whereas the reference compound cisplatin produced a dramatic and highly significant (Po0.001) effect.
Conditioned taste aversion (CTA). NNC 38-1049 did not induce any significant (Po0.05) CTA, as measured by saccharin preference (Figure 7 ) following a 7-day conditioning period in which rats were given a daily i.p. dose of Neural histamine and food intake K Malmlöf et al 20 mg/kg. In contrast, the reference compound LiCl was found to produce a highly significant (Po0.01) reduction of saccharine consumption.
Effects on the HPA axis. No signs of activation of the HPA axis were found, as evidenced by the plasma levels of corticosterone, for which no significant difference was found between vehicle and NNC 38-1049-treated rats (175735.1 vs 114.6721.7 ng/ml).
Food intake, energy expenditure and substrate oxidation following single dose Oral doses of NNC 38-1049 ranging from 15 to 60 mg/kg were found to produce significant (Po0.05) reductions in the accumulated amount of food consumed during a 3 h period following presentation of food in schedule-fed rats ( Figure 8) . None of the doses of NNC 38-1049 tested was associated with any significant changes in energy expenditure follow- Neural histamine and food intake K Malmlöf et al ing single dosing, although the respiratory quotient (RQ) (RER) tended to decrease at higher doses ( Figure 9 ). This tendency was particularly pronounced after administration of the highest dose, that is, 60 mg/kg.
Intakes of food and water, body weight and plasma variables following repeated dosing
In old DIO rats that had been trained to consume their daily food intake during a 7-h period, two daily administrations of NNC 38-1049 (2 Â 20 mg/kg), were found to result in a significantly (Po0.01) sustained reduction in food intake for 15 days. This inhibition was of the order of 25%, and was associated with a highly significant (Po0.01) decrease in body weight. The decrease in body weight was of the same magnitude as seen in animals that were restricted to eat no more than 75% of their normal intake of food ( Figure 10 ). Following the loss in body weight, there were no specific changes in the proportions of lean tissue and body fat (data not shown). 
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At a dose of 20 mg/kg, NNC 38-1049 significantly (Po0.01) decreased water intake in direct association with dosing ( Figure 11 ). Later, this was compensated for so that 24-h measurements of water intake in rats receiving NNC 38-1049 were not different from those found in rats receiving vehicle.
Plasma glucose, FFA and insulin remained generally unchanged after NNC 38-1049 dosing, whereas serum triglycerides were significantly (Po0.05) decreased in rats that had received the highest dose (Table 1) . What, in a first instance, looked like a concomitant increase in b-hydroxybutyrate and decrease in leptin was not found to be statistically significant following post hoc testing.
Discussion
In the present study, we demonstrate that NNC 38-1049 is a very potent and specific competitive antagonist at both the human and rat histamine H 3 receptor. This was evidenced by its ability to antagonize the effects of the well-known H 3 receptor agonist RAMHA on the intracellular cAMP concentration. These observations provide evidence that the in vivo effects discussed below can be attributed to antagonism at the histamine H 3 receptor.
NNC 38-1049 produced an increase in extracellular levels of histamine in the PVN. This original finding is interesting from the point of view that it has previously been demonstrated that the PVN plays a central role in the histaminergic regulation of food intake 21 and that it harbours a population of H 1 and H 3 receptors. 22 This finding adds further support to the view that the histamine H 3 receptor is essential for regulating the histamine release and synaptic histamine concentration, 15, 16, [23] [24] [25] and that this concentration can be increased Neural histamine and food intake K Malmlöf et al as thioperamide 26, 27 are associated with an acute decrease of food intake. In one study performed by Attoube et al, 28 these findings were reproduced also after peripheral administration of the same drug. The present work with NNC 38-1049 adds further support to these observations. In addition, we show that it is possible to sustain this effect on food intake over a prolonged period of time, and that a significant reduction in body weight is achieved. Our observations of BSS also imply that the effect on food intake can be separated from other unwanted behavioural changes, that is, that the reduction of food intake is specific. These data are in accordance with recently published observations with an H 3 receptor antagonist belonging to another structurally different class of compounds, 29 and increase the possibility for a future clinical use of an histamine H 3 receptor antagonist in obese humans. Moreover, NNC 38-1049, obviously, did not evoke visceral illness, since no increase in pica behaviour was observed. CTA is often used to examine potential side effects such as nausea or malaise. In most cases, this test is performed in acute settings. In an initial study, we found that NNC 38-1049 acutely induced CTA in a dose of 20 mg/kg, but not in doses of 10 or 30 mg/kg (data not shown). However, the most relevant question from a therapeutic and specificity point of view is, of course, whether the support of a potential CTA will be sustained during repeated administration. Previous experiences with other drugs have shown that the response to conditioning stimuli can change during repeated administration. 30 For this reason, we adopted a subchronic CTA paradigm, in which the conditioning period was prolonged to 7 days. In this paradigm, NNC 38-1049 did not induce a significant CTA. This adds further support to the conclusion that effects of NNC 38-1049 on food intake and body weight are specific and not due to inflictions on well-being. The fact that obese rats used in the present study lost a significant amount of weight may seem to contradict to the recent findings by Takahashi et al that histamine H 3 receptor knockout mice actually gained in weight and became obese. 31 However, we do not believe that this is necessarily the case. Intermittent increases in neural histamine by pharmacological means might have a quite different effect compared with a congenital form of histamine H 3 receptor disruption. In fact, Takahashi et al 31 found a certain decrease in H 1 receptor abundance in their histamine H 3 receptor knockout mice, which might explain the increase in food intake and concomitant increase in body weight. In the present study, no measurements of H 1 receptor abundance was performed, but such measurements would certainly help to clarify this issue, which of course is of vital importance for a thorough understanding of an anticipated difference between the pharmacological antagonism of the histamine H 3 receptor and complete genetic disruption. In this context, it is worth mentioning that NNC 38-1049 has a relatively short plasma half-life of about 20 min, which was the reason for the twice-daily dosing regimen. This also suggests that, in the present study, there was no carryover of drug exposure from one day to the other. This 'recovery' period could conceivably be of importance for the possibility of achieving a sustained reduction of food intake over a prolonged period of time.
In the present study, the reduction of food intake at the highest dose of NNC 38-1049 was approximately 25%, which was similar to that imposed on the food-restricted group. This similarity in energy intakes between the two groups was also reflected in a very similar loss of body weight. Moreover, body composition after weight loss did not differ between these groups. This observation fits well with our findings that NNC 38-1049 did not induce changes in daily water consumption and that there were no acute specific effects on energy expenditure. It has, however, to be emphasized that the measurements of energy expenditure were performed after administering a single dose in young growing animals and not in the dietary obese rats used in connection with repeated sampling. This fact may have decreased our possibilities of detecting such an effect on energy 32 The fact that, in the present study, we could not confirm an upregulation of energy expenditure in the acute situation does not exclude the possibility of this occurring after repeated dosing, and new studies investigating the more long-term effects of a histamine H 3 receptor antagonist on energy expenditure are in progress. It has also been suggested that histamine promotes lipolysis via stimulation of the sympathetic b-adrenoreceptor. 33 The reduction of the RQ that was observed after a single dose with the highest dose level of NNC 38-1049 indicates that lipid oxidation was increased in this situation. The depressed triglyceride levels observed after repeated administration of NNC 38-1049 are also in line with this. However, the reason why these changes in lipid metabolism did not translate into an accelerated loss of adiposity (data not shown) after prolonged administration compared with caloric restriction alone is presently not known, but could imply that the acute effects of NNC 38-1049 on lipid oxidation might change over time. In any case, these observations merit further investigation, and future studies will reveal the long-term effects of H 3 receptor antagonism on whole-body lipid oxidation and adiposity.
No major changes were seen in plasma levels of glucose, insulin and corticosterone, implying that specific targeting of the histamine H 3 receptor could be a sound and effective way of correcting obesity. It has previously been reported that i.c.v. injections of histamine elevate circulating levels of ACTH and corticosterone in rats. 34 One of the reasons that this was not observed in the present study could be that such effects are relatively transient. 34 Our animals were not bled in direct association with dosing of NNC 38-1049. Other differences in experimental design, for example, route of administration, could also have played a role.
In conclusion, the present study has addressed a number of critical issues in the evaluation of the concept of using antagonistic targeting of the histamine H 3 receptor to decrease food intake and body weight. The results presented here with NNC 38-1049, and also by others (for a review, see Leurs et al 35 ) , strongly support the idea that such selective antagonism represents a promising avenue for further research. The most urgent issue seems to be the identification of a candidate with similar or superior efficacy profile, as shown here with NNC 38-1049, but with a somewhat longer plasma half-life.
